HepatitisC, 2016.fact sheet N°164",July 2015. Retrieved 4 February -
Mohd HanafiahK,GroegerJ,FlaxmanAD,WiersmaST, 2013.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence,Hepatology 57 1333 -42
SirhindiGA,BajawaMA,AsifMJ,KhanLA,AlamgirMA, 2012.Frequency and different indications for anti-hcv screening,Pak J Med Health Sci 6 94 -6
FerraroD,GiglioM,BonuraC,Di MarcoV,MondelliMU,CraxìA, 2008.Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay,J Viral Hepat 15 66 -70
WilkinsH,MalcolmJK,RainaD,SchadeRR, 2010.Hepatitis C: diagnosis and treatment,Am Fam Physician 81 1351 -7
2013.Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians,MMWR Morb Mortal Wkly Rep 62 362 -5
BoyerTD,MannsMP,SanyalAJ,ZakimD.,Zakim, .Boyer's Hepatology: A Textbook of Liver Disease,pg 107. -
.Hepatitis C Virus (HCV) RNA detection and quantification by real-time reverse transcriptionPCR (RT-PCR), serum clinical information, -
DanielHD,GrantPR,GarsonJA,TedderRS,ChandyGM,AbrahamP, 2008.Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples,DiagnMicrobiol Infect Dis 61 415 -20
MumtazK,HamidSS,MoatterT,AbidS,ShahHA,JafriW., 2008.Distribution of hepatitis C virus genotypes and its response to treatment in Pakistani patients,Saudi Med J 29 1671 -3
ChevaliezS., 2011.Virological tools to diagnose and monitor hepatitis C virus infection,Clin Microbiol Infect 17 116 -21
SpachDH, 2015.Hepatitis C diagnostic testing, -
GuptaE,BajpaiM,ChoudharyA, 2014.Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays,Asian J Transfus Sci 8 19 -25
TrianniA,PaneerN,DenkingerC, 2015.High-priority target product profile for hepatitis C diagnosis in decentralized settings: Report of a consensus meeting,FIND 7 1 -42
FirdausR,SahaK,BiswasA,SadhukhanPC, 2015.Current molecular methods for the detection of hepatitis C virus in high risk group population: A systematic review,World J Virol 4 25 -32
DalgardO,BjoroK,Ring-LarsenH,VerbaanH., 2010.In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials,Eur J Gastroenterol Hepatol 22 552 -6
McEwanP,SelvapattN,BrownA,ThurszM,BennettH,WebsterS, 2017.A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective,Eur J Gastroenterol Hepatol 29 208 -14
DiagoM,ShiffmanML,BronowickiJP,ZeuzemS,RodriguezTorresM,PappasSC, 2010.Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin,Hepatology 51 1897 -903
NoellBC,BesurSV, 2015.Changing the face of hepatitis C management - the design and development of sofosbuvir,Drug Des Devel Ther 9 2367 -74
ZhangS,BastianND,GriffinPM, 2015.Cost-effectiveness of sofosbuvirbased treatments for chronic hepatitis C in the US,BMC Gastroenterol 15 98 -
SteinebrunnerN,SprinzlMF,ZimmermannT,WornsMA,ZimmererT,GallePR, 2015.Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort,BMC Gastroenterol 15 97 -
LawitzE,MangiaA,WylesD,Rodriguez-TorresM,HassaneinT,GordonSC, 2013.Sofosbuvir for previously untreated chronic hepatitis C infection,N Engl J Med 368 1878 -87
StedmanC, 2014.Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential,Therap Adv Gastroenterol 7 131 -40
Rodriguez-TorresM,SulkowskiMS,ChungRT,HamzehFM,JensenDM, 2010.Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population,J Viral Hepat 17 139 -147
DalgardO,Martinot-PeignouxM,VerbaanH,BjøroK,RingLarsenH,MarcellinP., 2015.The usefulness of defining rapid virological response by a very sensitive assay (TMA) during treatment of HCV genotype 2/3 infection,PLoSOne 10 e0120866 -